James Nevin

James Nevin is a Research Fellow at Yale School of Medicine, Yale University. His research focuses on immunology, cancer biology, and neuroimmunology, with particular emphasis on the roles of β-adrenergic signaling, sympathetic nervous system regulation, and immune cell dynamics in cancer and autoimmune contexts. His work explores how neuroendocrine signaling influences natural killer cells, myeloid-derived suppressor cells, and T cell dysfunction. Recent studies highlight the modulation of tumor immunity via sympathetic tone and the therapeutic potential of anti-TIGIT antibodies.

His publications from 2018 to 2024 reveal a consistent exploration of neuroimmune interactions, tumor microenvironment dynamics, and co-inhibitory pathways in T cells. Notable topics include the impact of endogenous opioids on T cell dysfunction in melanoma and the genetic modifiers of Mertk loss-of-function traits.

No scientific awards or grants are explicitly mentioned in the provided data. No advising roles or lab affiliations are detailed in the text, though his research aligns with broader initiatives in immunotherapy and cancer biology at Yale.